

	Month (%)	Quarter (%)	1 Year (%)	2 Years (% p.a.)	3 Years (% p.a.)	Since Inception^ (% p.a.)	Since Inception Cumulative^ (%)
eInvest Better Future Fund (Managed Fund)	-1.2	1.0	-11.2	-1.4	16.0	6.5	27.7
S&P/ASX Small Ordinaries Accumulation Index	-0.7	1.9	-13.2	-2.4	13.1	2.5	10.0
<b>Value Added</b>	<b>-0.5</b>	<b>-0.9</b>	<b>2.0</b>	<b>1.0</b>	<b>2.9</b>	<b>4.0</b>	<b>17.7</b>

^Inception date was 23 May 2019. Performance shown above are net of fees. Fund returns are calculated using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or the bid ask spread that investors incur when buying and selling units on the ASX. Past performance is not a reliable indicator of future performance.

## Overview

The benchmark declined 0.7% in March as the collapse of Silicon Valley Bank weighed on sentiment, although the market rallied towards month end as it appeared that global contagion is unlikely and that the interest rate hiking cycle may be nearing completion, particularly in Australia. The Fund declined -1.2% after fees during the month, underperforming by 0.5%.

Positive contributors to relative performance during March included Alpha HPA (+25.7%), Impedimed (+75.0%), PEXA Group (+13.9%) and Meridian Energy (+2.9%).

Negative contributors to relative performance during the month included Janison Education (-34.0%), Calix (-17.9%), Charter Hall Group (-17.4%) and Healthco Healthcare and Wellness REIT (-16.5%).

## Better Future Highlight

During the month, Impedimed announced that the US National Comprehensive Cancer Network (“NCCN”) Clinical Practice Guidelines in Oncology have been revised to recommend objective measurement and routine screening for lymphoedema assessment in cancer patients. Lymphoedema is a chronic and often significant swelling in a limb that can occur as a side effect of cancer treatment when lymph nodes have been removed or damaged. While the recommendation applies to all cancer patients, this condition is most common in breast cancer patients. The guidelines now specifically name bioimpedance spectroscopy (“BIS”) as a screening tool for lymphoedema and Impedimed’s SOZO platform is the only FDA-cleared BIS technology for the assessment of lymphoedema. This decision was unanimous by the committee that oversees the process. This is a significant, long-awaited milestone for the company and is expected to lead to reimbursement from private health insurers in the US for the SOZO test. This will materially improve revenue from the SOZO platform, particularly in the US market. While this is a positive for the company, it is also a positive for cancer survivors who are at risk of suffering from lymphoedema as the SOZO technology is more likely to detect lymphoedema before the symptoms become significant than is currently the case.

## eInvest Better Future Fund (Managed Fund)

The aim of IMPQ is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance (“ESG”) considerations and/or businesses that are making a positive contribution to creating a better future. IMPQ seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index.

### Portfolio Manager

Damian Cottier

### IMPQ FUM

\$39 million

### Distribution Frequency

Annually (if any)


### Fees

0.99% p.a. (incl of GST and RITC)  
+ Performance fee

### Inception Date


23 May 2019

## Growth of \$100,000 Since Inception



Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

## Portfolios Contribution to the UN Sustainable Development Goals



## Fund Review

The benchmark declined 0.7% in March as the collapse of Silicon Valley Bank weighed on sentiment, although the market rallied towards month end as it appeared that global contagion is unlikely and that the interest rate hiking cycle may be nearing completion, particularly in Australia. The Fund declined -1.2% after fees during the month, underperforming by 0.5%.

Positive contributors to relative performance during March included Alpha HPA (+25.7%), Impedimed (+75.0%), PEXA Group (+13.9%) and Meridian Energy (+2.9%).

Negative contributors to relative performance during the month included Janison Education (-34.0%), Calix (-17.9%), Charter Hall Group (-17.4%) and Healthco Healthcare and Wellness REIT (-16.5%).

Alpha HPA announced that it had reached an agreement with global industrial company Ebner Industrieofenbau to enable Alpha to produce synthetic sapphire glass which is a downstream product of the company's high-purity alumina ("HPA") production process. Sapphire glass is used in LED lighting, optics and consumer electronics. Ebner has developed an advanced sapphire glass production technology and selected Alpha as a partner after testing Alpha's products since mid-2022. This agreement will result in the production of value-added product in Australia at the company's Gladstone, Queensland production facility using Ebner's low energy technology and Alpha's high-purity alumina. Alpha's production process results in HPA which has around 70% lower total emissions compared to incumbent processes.

The Impedimed share price responded positively to the announcement referred to in the "Better Future Highlight" section above in relation to the NCCN Clinical Practice Guidelines changes.

There were no negative announcements from Janison or Calix during the month. Janison did announce an incremental positive in that it has entered into an agreement with the University of Sydney. Under the agreement, Janison will partner with the university in relation to both the promotion of Janison's ICAS assessment competition product - where Janison will be able to use the University of Sydney name in promotion - and the extension of Janison's Data-Led Education Equity Program ("DEEP") into target communities. The DEEP program uses student data derived from digital assessments to drive improvements in student learning outcomes. The initiative will see Janison provide student benchmarking assessments and the ICAS competition to students in years 5-10 in regional, remote, very remote, Indigenous and low socioeconomic schools over the next 2 years.

Charter Hall Group was impacted by the general weakness in real estate stocks during the month despite the 10-year bond yield falling significantly in both the US and Australia. Healthco raised capital at a discount late in the month to fund the acquisition of a portfolio of hospital properties which we see as an incremental positive in improving the quality of the portfolio.

At month end, the portfolio held 43 stocks and cash of 7.6%.

At March end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Fund was 7.3 which is 29% higher than the benchmark ESGE Score of 5.6.

## ESG Activity

Our ESG activity during the month included:

- Meridian Energy raised \$200m in green bonds for renewable energy and energy efficiency projects.
- KMD Brands achieved Group-wide B Corp Status, which is one of the first multinational companies in Australia & New Zealand to have all its brands individually certified. We also engaged with KMD on cyber security risk management & governance.
- We participated in the Bendigo Bank ESG materiality study to assist them with ESG priorities.
- Perennial Better Future Trust was re-certified as a Responsible Investment Product by RIAA as part of RIAA's rigorous Certification program.
- We emailed companies in our portfolio to encourage measurement and disclosure of GHG emission in line with our reporting targets. We were met with constructive responses from Charter Hall, Pacific Edge, Immutept & Opthea.
- The 4<sup>th</sup> annual Perennial Better Future Survey was released. [See here.](#)
- Perennial Better Future released the third annual Impact statement. [See here.](#)
- Perennial Better Future participated in an FPA webinar titled "[ESG Analysis vs Sustainable Investing](#)".
- Members across the Perennial team (including Perennial Better Future) undertook a corporate volunteer day at Wayside Chapel.
- Perennial held the first Diverse Boards Event in collaboration with Perennial Better Future, Smaller Companies and Private Investments. The event connected female NEDs in our network with our portfolio companies, aiming to produce meaningful introductions to facilitate increased board gender diversity.

Top 5 Portfolio Positions	IMPQ (%)	Index (%)
Meridian Energy Ltd	5.2	0.0
Telix Pharmaceuticals Ltd	5.0	0.7
Sims Ltd	4.9	1.1
Chorus Ltd	4.5	1.5
AUB Group Ltd	4.0	1.0



Portfolio Manager, Damian Cottier (right) and Co-Head of ESG & Equities Analyst, Emilie O'Neill (left)

## Contact us



Level 27, 88 Phillip Street  
Sydney NSW 2000



1300 420 094



invest@perennial.net.au



www.perennial.net.au

Issued by Perennial Value Management Limited (ABN 22 090 879 904, AFSL No. 247293) as the Investment Manager. The Responsible Entity is Perennial Investment Management Limited (ABN 13 108 747 637, AFSL No. 275101). Perennial Partners Limited (ABN 90 612 829 160) is a Corporate Authorised Representative (1293138) of Perennial Value Management Limited. Both the Investment Manager and Responsible Entity form part of Perennial Partners. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation and is not intended to constitute advertising or advice of any kind and you should not construe the contents of promotional statement as legal, tax, investment or other advice. This promotional statement does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. While every effort has been made to ensure the information in this promotional statement is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. The current relevant product disclosure statement and target market determination can be found on Perennial's website [www.perennial.net.au](http://www.perennial.net.au). Use of the information on our website is governed by Australian law and is subject to the terms of use. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful.